Porosome Therapeutics

Executive Summary

Porosome Therapeutics is a San Diego-based biotechnology company pioneering a novel approach to treating diseases by targeting the 'porosome,' the universal secretory machinery in cells. Founded in 2018, the company leverages cryo-electron microscopy (cryo-EM) and artificial intelligence (AI) to solve the atomic structures of porosomes and design small molecules that correct secretory defects. Its initial focus is on neurodegenerative diseases such as Alzheimer's and genetic disorders like cystic fibrosis. By addressing fundamental cellular secretion mechanisms, Porosome aims to develop first-in-class therapies for conditions with high unmet need. The company is at an early stage, having completed structural biology groundwork and now moving toward lead optimization and preclinical development. With no disclosed funding rounds or pipelines, Porosome remains a high-risk, high-reward opportunity dependent on successful proof-of-concept studies and securing additional capital.

Upcoming Catalysts (preview)

• Q4 2026Lead optimization and preclinical candidate nomination35% success
• H1 2026Series A funding round50% success
• Q2 2026Presentation of structural data at major conference70% success